Naturally occurring T cell mutations enhance engineered T cell therapies

Authors:
Garcia J, Daniels J, Lee Y, Zhu I, Cheng K, Liu Q, Goodman D, Burnett C, Law C, Thienpont C, Alavi J, Azimi C, Montgomery G, Roybal KT, Choi J
In:
Source: Nature
Publication Date: (2024)
Issue: 626(7999): 626-634
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Gene Expression
Basic Research
Molecular Biology
Regenerative medicine
Cells used in publication:
T cell, human stim.
Species: human
Tissue Origin: blood
Jurkat-modified
Species: human
Tissue Origin:
Culture Media:
Platform:
4D-Nucleofector® 96-well Systems
4D-Nucleofector® X-Unit
Experiment

Primary human T cell isolation and culture

After thawing, T cells were cultured in human T cell medium consisting of X-VIVO 15 (Lonza No. 04-418Q), 5% human AB serum and 10 mM neutralized N-acetyl l-cysteine (Sigma-Aldrich No. A9165); for in vitro assays, medium was supplemented with 30 units per millilitre of IL-2 (NCI BRB Preclinical Repository), and for experiments involving TCR gene knockout, human T cell medium was supplemented with 100 units per millilitre of IL-7 (Miltenyi No. 130-095-362) and 100 units per millilitre of IL-15 (Miltenyi No. 130-095-765).

TCR gene knockout of lentivirally transduced human T cells

For TCR gene knockout experiments, primary T cells were activated and transduced as indicated above. At 24 h post transduction, virus and Dynabeads were removed, and cells were rested for 24 h, and then resuspended at 1 × 10^6 cells per millilitre in P3 electroporation buffer (Lonza No. V4SP-3960) with sgRNA (CAGGGUUCUGGAUAUCUGU) targeting the human TRAC locus and Cas9. A 23 µl volume of this mixture was aliquoted to each well of a 96-well nucleofection plate (Lonza No. V4SP-3960) and immediately electroporated using a 4D Lonza Nucleofector with program EH-115. Cells were resuspended in pre-warmed human T cell medium and recovered for 30 min in the incubator before being transferred to culture. Electroporated cells were assessed for TCR gene knockout and lentiviral transduction through flow before injection into mice.

CARD11 and BCL10 CRISPR knockout
CRISPR knockout was carried out in triple-reporter Jurkat cells using the SE Cell Line 4D-Nucleofector Kit (Lonza). A total of 1 × 10^6 cells were nucleofected with Cas9 alone or ribonuclear protein complexes of Cas9 with CARD11 gRNA (CAATGACCTTACACTGACGC) or BCL10 gRNA (TCGCCGAATAGATTCAACAA).

Abstract

Adoptive T cell therapies have produced exceptional responses in a subset of patients with cancer. However, therapeutic efficacy can be hindered by poor T cell persistence and function1. In human T cell cancers, evolution of the disease positively selects for mutations that improve fitness of T cells in challenging situations analogous to those faced by therapeutic T cells. Therefore, we reasoned that these mutations could be co-opted to improve T cell therapies. Here we systematically screened the effects of 71 mutations from T cell neoplasms on T cell signalling, cytokine production and in vivo persistence in tumours. We identify a gene fusion, CARD11-PIK3R3, found in a CD4+ cutaneous T cell lymphoma2, that augments CARD11-BCL10-MALT1 complex signalling and anti-tumour efficacy of therapeutic T cells in several immunotherapy-refractory models in an antigen-dependent manner. Underscoring its potential to be deployed safely, CARD11-PIK3R3-expressing cells were followed up to 418 days after T cell transfer in vivo without evidence of malignant transformation. Collectively, our results indicate that exploiting naturally occurring mutations represents a promising approach to explore the extremes of T cell biology and discover how solutions derived from evolution of malignant T cells can improve a broad range of T cell therapies.